INTRODUCTION

Myofibroblastoma (MFB) is a benign mesenchymal entity. It is a rare tumor with a prevalence of less than 1% of all breast tumors.¹ It is more common in postmenopausal women and middle- to older men. Although its etiology has not been fully understood, cases with a history of steroid hormone use, gynecomastia, chest wall trauma, and surgical scars have been reported in the literature.² Although MFB is a benign entity, in radiological evaluation, there is no specific diagnostic feature³. The mDIXON quant sequence is a chemical shift encoding based on proton density fat fraction, which can assess fat content quantitatively with fat fraction value.⁴ In this case report, we present the mDIXON quant magnetic resonance imaging (MRI) findings of MFB. To the best of our knowledge, this is the first case presenting mDIXON quant MRI findings of MFB in the published literature.

CASE PRESENTATION

A 55-year-old male patient with a complaint of abdominal pain underwent abdominal MRI. Although he had no history of cancer in his own and family history, he had a subcutaneous lipoma at the lower thoracic levels on the right anterior axillary line for a long time. An abdominal MRI examination included upper extraabdominal sites up to the retroaerolar region. In this examination, there were solid lesions in both retroareolar areas. The most significant lesion was located at the left retroareolar localization (Figure 1A, B). In our institute, routine abdominal MRI protocol includes another sequence called mDIXON quant, showing macroscopic-microscopic fat and water content (Figure 2). In the macroscopic fat content measurements with the lesion’s largest diameter, the lesion contained 22.51% fat, and the lesion T2 relaxation time was measured as 82.03 ms (Figure 3A, B). In the coloured maps created in the section that passed through the lesion level, the percentage of fat contained in the lesion was shown in the appropriate color (Figure 3C, D). Mammography and breast ultrasonography were recommended for further examination. The left retroareolar solid lesion was excised because of breast evaluation. Histopathological diagnosis of the lesion has been reported as (MFB) (Figure 4).

DISCUSSION

MFB belongs to the family of CD34-positive tumors and is characterized by spindle-shaped cells growing in collagen bands and variable numbers of fat-containing fascicles.³

The mDIXON quant sequence is a proton-density-based chemical shift encoding that uses a fat fraction value to quantitatively analyze fat content.⁴ This sequence consists of four separate series: in-phase, out-phase, water only, and fat only, using mathematical calculations taking advantage of the T2^* relaxation time difference of fat and water. In this way, it is possible to make fat rate measurements that give meaningful results in different organs and lesions using this sequence, which is generally used in the abdominal region.⁵

Because MFB is a rare disease and includes variable amounts of fat-containing fascicles, the mDIXON quant sequence provides a prominent contribution in evaluating fat content in the lesion. By using this sequence, quantification of fat can be made. Additionally, this sequence provides us with better management in the evaluation and treatment of similar lesions. Written informed consent was obtained from the patient who participated in this study.

MAIN POINTS

• The mDIXON quant sequence is a chemical shift encoding based on proton density fat fraction, which can assess fat content quantitatively with fat fraction value.

• It is possible to make fat rate measurements that give meaningful results in different organs and lesions using the mDIXON sequence, which is generally used in the abdominal region.

• Because MFB is a rare disease and includes variable amounts of fat-containing fascicles, the mDIXON quant sequence provides a prominent contribution in evaluating fat content in the lesion.

• The mDIXON sequence provides us with better management in the evaluation and treatment of similar lesions.

ETHICS

Informed Consent: Written informed consent was obtained from the patient who participated in this study.

Peer-review: Externally and internally peer-reviewed.

Authorship Contributions

Concept: H.A.Ö., Design: I.B.A., C.A., M.G.D., Supervision: I.B.A., P.B., Fundings: H.A.Ö., M.G.D., Materials: I.B.A., M.G.D., Data Collection and/or Processing: H.A.Ö., M.G.D., Analysis and/or Interpretation: I.B.A., Literature Search: C.A., P.B., Writing: H.A.Ö., C.A., P.B., Critical Review: C.A., P.B.

DISCLOSURES

Conflict of Interest: The authors have no conflicts of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.